Do analysts recommend SBTX or RYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate RFAI or RYM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RF Acquisition Corp II 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, RFAI or RYM?

RF Acquisition Corp II has higher earnings, but lower revenue than RYTHM. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RF Acquisition Corp II N/A N/A N/A N/A N/A RYTHM $17.28M 3.16 -$33.26M -$10.53 N/A

Do analysts rate RYM or LFCR?

Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 49.43%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifecore Biomedical 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer RYM or MENS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, RYM or MENS?

Jyong Biotech has lower revenue, but higher earnings than RYTHM. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RYTHM $17.28M 3.16 -$33.26M -$10.53 N/A Jyong Biotech N/A N/A -$4.67M N/A N/A

Is RYM or MENS more profitable?

Jyong Biotech has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Jyong Biotech's return on equity of 0.00% beat RYTHM's return on equity. Company Net Margins Return on Equity Return on Assets RYTHM -6.20% -12.57% -2.60% Jyong Biotech N/A N/A N/A

Do analysts prefer RYM or AARD?

Aardvark Therapeutics has a consensus target price of $15.33, indicating a potential upside of 167.60%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42

RYTHM (RYM) Competitors

$25.04 +1.04 (+4.33%)

As of 09/3/2026 03:34 PM Eastern

Compare

RYM vs. SBTX, RFAI, LFCR, MENS, and AARD

Should you buy RYTHM stock or one of its competitors? RYTHM's main competitors and comparable companies include Silverback Therapeutics (SBTX), RF Acquisition Corp II (RFAI), Lifecore Biomedical (LFCR), Jyong Biotech (MENS), and Aardvark Therapeutics (AARD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does RYTHM compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 6.0% of RYTHM shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 3.5% of RYTHM shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Silverback Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market. Comparatively, RYTHM has a beta of 9.44, suggesting that its stock price is 844% more volatile than the broader market.

In the previous week, Silverback Therapeutics' average media sentiment score of 0.00 equaled RYTHM'saverage media sentiment score.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
RYTHM	Neutral

Silverback Therapeutics has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Silverback Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
RYTHM	-6.20%	-12.57%	-2.60%

RYTHM has higher revenue and earnings than Silverback Therapeutics. Silverback Therapeutics is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
RYTHM	$17.28M	3.16	-$33.26M	-$10.53	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

RYTHM beats Silverback Therapeutics on 7 of the 11 factors compared between the two stocks.

How does RYTHM compare to RF Acquisition Corp II?

RF Acquisition Corp II (NASDAQ:RFAI) and RYTHM (NASDAQ:RYM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

In the previous week, RF Acquisition Corp II's average media sentiment score of 0.00 equaled RYTHM'saverage media sentiment score.

Company	Overall Sentiment
RF Acquisition Corp II	Neutral
RYTHM	Neutral

RF Acquisition Corp II has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RF Acquisition Corp II's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RF Acquisition Corp II	N/A	N/A	N/A
RYTHM	-6.20%	-12.57%	-2.60%

6.0% of RYTHM shares are owned by institutional investors. 39.1% of RF Acquisition Corp II shares are owned by insiders. Comparatively, 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

RF Acquisition Corp II has a beta of 1.16, indicating that its stock price is 16% more volatile than the broader market. Comparatively, RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RF Acquisition Corp II	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

RF Acquisition Corp II has higher earnings, but lower revenue than RYTHM.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RF Acquisition Corp II	N/A	N/A	N/A	N/A	N/A
RYTHM	$17.28M	3.16	-$33.26M	-$10.53	N/A

Summary

RF Acquisition Corp II beats RYTHM on 4 of the 7 factors compared between the two stocks.

How does RYTHM compare to Lifecore Biomedical?

RYTHM (NASDAQ:RYM) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

RYTHM has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than RYTHM, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	3.16	-$33.26M	-$10.53	N/A
Lifecore Biomedical	$128.87M	1.28	-$40.50M	-$1.07	N/A

In the previous week, Lifecore Biomedical had 4 more articles in the media than RYTHM. MarketBeat recorded 4 mentions for Lifecore Biomedical and 0 mentions for RYTHM. Lifecore Biomedical's average media sentiment score of 0.73 beat RYTHM's score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
RYTHM	Neutral
Lifecore Biomedical	Positive

Lifecore Biomedical has a consensus target price of $6.50, suggesting a potential upside of 49.43%. Given Lifecore Biomedical's stronger consensus rating and higher probable upside, analysts plainly believe Lifecore Biomedical is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

RYTHM has a net margin of -6.20% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Lifecore Biomedical	-29.93%	N/A	-16.16%

RYTHM has a beta of 9.44, suggesting that its stock price is 844% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market.

6.0% of RYTHM shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Lifecore Biomedical beats RYTHM on 10 of the 16 factors compared between the two stocks.

How does RYTHM compare to Jyong Biotech?

RYTHM (NASDAQ:RYM) and Jyong Biotech (NASDAQ:MENS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, Jyong Biotech had 1 more articles in the media than RYTHM. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for RYTHM. RYTHM's average media sentiment score of 0.00 equaled Jyong Biotech'saverage media sentiment score.

Company	Overall Sentiment
RYTHM	Neutral
Jyong Biotech	Neutral

Jyong Biotech has lower revenue, but higher earnings than RYTHM.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	3.16	-$33.26M	-$10.53	N/A
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A

Jyong Biotech has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. Jyong Biotech's return on equity of 0.00% beat RYTHM's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Jyong Biotech	N/A	N/A	N/A

RYTHM has a beta of 9.44, meaning that its share price is 844% more volatile than the broader market. Comparatively, Jyong Biotech has a beta of 2.24, meaning that its share price is 124% more volatile than the broader market.

6.0% of RYTHM shares are held by institutional investors. 3.5% of RYTHM shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Jyong Biotech beats RYTHM on 5 of the 9 factors compared between the two stocks.

How does RYTHM compare to Aardvark Therapeutics?

RYTHM (NASDAQ:RYM) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

RYTHM has a beta of 9.44, meaning that its stock price is 844% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.74, meaning that its stock price is 274% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 24 more articles in the media than RYTHM. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 0 mentions for RYTHM. Aardvark Therapeutics' average media sentiment score of 0.03 beat RYTHM's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
RYTHM	Neutral
Aardvark Therapeutics	Neutral

RYTHM has higher revenue and earnings than Aardvark Therapeutics. RYTHM is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	3.16	-$33.26M	-$10.53	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

Aardvark Therapeutics has a consensus target price of $15.33, indicating a potential upside of 167.60%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aardvark Therapeutics is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

Aardvark Therapeutics has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

6.0% of RYTHM shares are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aardvark Therapeutics beats RYTHM on 10 of the 16 factors compared between the two stocks.

Get RYTHM News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYM vs. The Competition

Export

Metric	RYTHM	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$52.30M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-2.38	787.27	273.29	25.38
Price / Sales	3.16	753.78	613.45	97.56
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	1.40	12.33	12.89	6.14
Net Income	-$33.26M	$2.82B	$3.47B	$349.01M
7 Day Performance	8.16%	2.59%	0.60%	-0.27%
1 Month Performance	-1.57%	6.95%	5.73%	0.68%
1 Year Performance	N/A	9.45%	25.35%	14.84%

RYTHM Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYM RYTHM	0.4072 of 5 stars	$25.04 +4.3%	N/A	N/A	$52.30M	$17.28M	N/A	140	High Trading Volume
SBTX Silverback Therapeutics	N/A	$5.35 -2.8%	N/A	-47.7%	$192.91M	N/A	N/A	83	High Trading Volume
RFAI RF Acquisition Corp II	0.5948 of 5 stars	$51.09 +0.1%	N/A	+293.8%	$179.28M	N/A	N/A	N/A
LFCR Lifecore Biomedical	2.2612 of 5 stars	$4.64 +2.0%	$6.50 +40.1%	-43.6%	$172.23M	$128.87M	N/A	690
MENS Jyong Biotech	N/A	$2.23 +0.5%	N/A	-96.0%	$168.78M	N/A	N/A	31	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYM) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RYTHM (RYM) Competitors

RYM vs. SBTX, RFAI, LFCR, MENS, and AARD

How does RYTHM compare to Silverback Therapeutics?

Summary

How does RYTHM compare to RF Acquisition Corp II?

Summary

How does RYTHM compare to Lifecore Biomedical?

Summary

How does RYTHM compare to Jyong Biotech?

Summary

How does RYTHM compare to Aardvark Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM vs. The Competition

RYTHM Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RYTHM (RYM) Competitors

RYM vs. SBTX, RFAI, LFCR, MENS, and AARD

How does RYTHM compare to Silverback Therapeutics?

Do institutionals & insiders believe in SBTX or RYM?

Which has more risk and volatility, SBTX or RYM?

Does the media favor SBTX or RYM?

Is SBTX or RYM more profitable?

Which has better valuation & earnings, SBTX or RYM?

Do analysts recommend SBTX or RYM?

Summary

How does RYTHM compare to RF Acquisition Corp II?

Does the media refer more to RFAI or RYM?

Is RFAI or RYM more profitable?

Do insiders & institutionals have more ownership in RFAI or RYM?

Which has more volatility & risk, RFAI or RYM?

Do analysts rate RFAI or RYM?

Which has preferable valuation & earnings, RFAI or RYM?

Summary

How does RYTHM compare to Lifecore Biomedical?

Which has higher earnings and valuation, RYM or LFCR?

Does the media prefer RYM or LFCR?

Do analysts rate RYM or LFCR?

Is RYM or LFCR more profitable?

Which has more risk & volatility, RYM or LFCR?

Do insiders & institutionals hold more shares of RYM or LFCR?

Summary

How does RYTHM compare to Jyong Biotech?

Does the media prefer RYM or MENS?

Which has stronger earnings & valuation, RYM or MENS?

Is RYM or MENS more profitable?

Which has more risk and volatility, RYM or MENS?

Do insiders & institutionals have more ownership in RYM or MENS?

Do analysts prefer RYM or MENS?

Summary

How does RYTHM compare to Aardvark Therapeutics?

Which has more volatility and risk, RYM or AARD?

Does the media prefer RYM or AARD?

Which has better valuation & earnings, RYM or AARD?

Do analysts prefer RYM or AARD?

Is RYM or AARD more profitable?

Do insiders and institutionals have more ownership in RYM or AARD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYM vs. The Competition

RYTHM Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools